{
    "2021-01-22": [
        [
            {
                "time": "2021-02-01",
                "original_text": "Dow Jones Dips As Intel, IBM Weigh; Nasdaq Hits New High Ahead Of Apple Earnings",
                "features": {
                    "keywords": [
                        "Dow",
                        "Jones",
                        "Dips",
                        "Intel",
                        "IBM",
                        "Nasdaq",
                        "High",
                        "Apple",
                        "Earnings"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "technology",
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-02-01",
                "original_text": "Top Coronavirus Vaccine Makers Will Earn Up to $23 Billion in Revenue This Year, Says New Analysis",
                "features": {
                    "keywords": [
                        "Coronavirus",
                        "Vaccine",
                        "Revenue",
                        "Analysis"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-02-01",
                "original_text": "HR tech company Workhuman looks to build employee connections amid pandemic",
                "features": {
                    "keywords": [
                        "HR",
                        "tech",
                        "Workhuman",
                        "employee",
                        "connections",
                        "pandemic"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "technology",
                        "human resources"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-02-01",
                "original_text": "Glaxo (GSK) Gets FDA Nod for Long-Acting HIV Regimen Cabenuva",
                "features": {
                    "keywords": [
                        "Glaxo",
                        "GSK",
                        "FDA",
                        "HIV",
                        "Regimen",
                        "Cabenuva"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-02-01",
                "original_text": "Johnson & Johnson Aims for 100 Million Vaccine Doses by Spring. The Stock Market Is Counting on It.",
                "features": {
                    "keywords": [
                        "Johnson",
                        "Johnson",
                        "Vaccine",
                        "Doses",
                        "Stock",
                        "Market"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-02-01",
                "original_text": "J&J (JNJ) to Get the Ball Rolling for Pharma Q4 Earnings",
                "features": {
                    "keywords": [
                        "J&J",
                        "JNJ",
                        "Pharma",
                        "Q4",
                        "Earnings"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-02-01",
                "original_text": "Pharma Stock Roundup: FDA Nod to MRK, AZN, JNJ, GSK Drugs, LLY's New Antibody Deal",
                "features": {
                    "keywords": [
                        "Pharma",
                        "Stock",
                        "FDA",
                        "MRK",
                        "AZN",
                        "JNJ",
                        "GSK",
                        "LLY",
                        "Antibody",
                        "Deal"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-02-01",
                "original_text": "Is Novavax Stock A Buy As Pressure Mounts For More Covid Vaccines?",
                "features": {
                    "keywords": [
                        "Novavax",
                        "Stock",
                        "Buy",
                        "Pressure",
                        "Covid",
                        "Vaccines"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-02-01",
                "original_text": "Johnson & Johnson Could Have 100 Million COVID-19 Vaccines By April, Board Member McClellan Says",
                "features": {
                    "keywords": [
                        "Johnson",
                        "Johnson",
                        "COVID-19",
                        "Vaccines",
                        "April",
                        "Board",
                        "Member",
                        "McClellan"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-02-01",
                "original_text": "3 Cheap Dividend Aristocrats to Buy Right Now",
                "features": {
                    "keywords": [
                        "Cheap",
                        "Dividend",
                        "Aristocrats",
                        "Buy"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance",
                        "investments"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}